

NAME	POSITION TITLE
Erasmus, Jeremy John	Professor, Department of Diagnostic Radiology MD Anderson Cancer Center, 2001-present

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of the Witwatersrand, Johannesburg, South Africa	MBBCh	1982	Bachelor of Medicine/Bachelor of Surgery
Baragwanath Hospital, Soweto, South Africa	Clinical Internship	1983	General Surgery, Internal Medicine, and Pediatric Orthopedics
Queen's University, Kingston, Ontario, Canada	Clinical Residency	1989	Diagnostic Radiology
Duke University Medical Center, Durham, NC	Clinical Fellowship	1994	Thoracic Imaging

#### **A. Personal Statement**

I am a Professor of Diagnostic Radiology in the Department of Diagnostic Imaging at the University of Texas M D Anderson Cancer Center (MDACC) and am currently the Section Chief of Thoracic Imaging. I have been a member of and have held leadership positions in a number of national and international radiology organizations, including the World Congress of Thoracic Imaging, Society of Thoracic Radiology, Radiological Society of North America, American Roentgen Ray Society, and American College of Radiology Imaging Network (ACRIN). I am the immediate past-president of the Society of Thoracic Radiology (STR). Along with my colleagues, I have been extensively involved in evaluating the role of imaging (including chest radiographs, CT and PET/CT, MRI) in oncology patients with a special interest in lung cancer and with an emphasis on detection and staging and assessing tumor response. I have a strong interest in lung cancer screening and served as a collaborator in the National Lung Screening Trial (NLST) site for MD Anderson Cancer Center (MDACC) and continue to be involved in the evaluation and publication of NLST data. Additionally, I am the PI of the Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening at MDACC.

#### **B. Positions and Employment**

1995-2000	Assistant Professor, Department of Radiology, Duke University Medical Center, Durham, NC
2001-2005	Associate Professor, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
2005-present	Professor, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
2007-present	Section Chief, Thoracic Imaging, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Other Experience and Professional Memberships**

1993-present	Member, American Roentgen Ray Society
1993-present	Member, Radiological Society of North America
1998-2014	Member, Scientific Poster Exhibit Panel, Radiological Society of North America
2003-present	Member, American Society of Clinical Oncology
2003-2014	Oral Examiner, Diagnostic Radiology, American Board of Radiology

2004-present Committee Member, American College of Radiology Imaging Network

2004-present Academy of Molecular Imaging/Journal of Molecular Imaging and Biology

2005-present Member, Journal of Thoracic Imaging Editorial Board

2006-2007 Member, International Scientific Committee, 12th World Conference on Lung Cancer, International Association for the Study of Lung Cancer

2006-2011 Member of Instructional Course Committee, American Roentgen Ray Society

2006-2011 Chair, Research Committee, Society of Thoracic Radiology (STR)

2006-2014 Member, Radiographics Education Editorial Board

2006-2014 Associate Editor, RadioGraphics

2006-2014 Chair, Chest Panel Committee, Radiological Society of North America

2006-present Fellow Member, Society of Computed Body Tomography and Magnetic Resonance

2008-2009 Core Program Committee Member for 2009 World Conference Lung Cancer Scientific Program, International Association for the Study of Lung Cancer

2008-present Member, Diagnostic Radiology Executive Committee, The University of Texas MD Anderson Cancer Center, Houston, TX

2009-present Associate Editor, Journal of Thoracic Oncology

2010-2011 Member, Promotions and Tenure Committee, The University of Texas MD Anderson Cancer Center, Houston, TX

2010 Member, Program Committee for Cancer Imaging and Radiation Therapy Symposium: A Multidisciplinary Approach, Radiological Society of North America

2010-present Member, Radiology Imaging Network

2010-present Mesothelioma Advisory Board of the IASLC International Staging Project in Malignant Pleural Mesothelioma, International Association for the Study of Lung Cancer

2011-present Interdisciplinary Forum-CCSG Lung Cancer Program, MDACC

2011-2013 Chair, Publications Committee, Society of Thoracic Radiology (STR)

2012-2013 Secretary, Society of Thoracic Radiology (STR)

2012-2014 Member, Budget and Finance Committee, Society of Thoracic Radiology (STR)

2013-2014 Member, Rules Committee, Society of Thoracic Radiology (STR)

2014 President, Society of Thoracic Radiology (STR)

2014-present Section Editor, Cancer

2014-present Member, Lung Cancer Screening Program, MDACC

2014-present Member, Lung Moon Shot Executive Committee, MDACC

2014-present Member, Moon Shot Gemini Committee, MDACC

2014-present Member, Oncology Expert Advisory Committee, MDACC

2014 Invited speaker, Lung cancer screening: how to do it. Diseases of the Heart and Chest, Including Breast, 47th International Diagnostic Course Davos Excellence in Teaching

2014 Organizer / Course Director, American Roentgen Ray Society 114th Annual Meeting Instructional Chest Course, Lung Cancer Screening: A Practical Approach

2015 Course co-director, American College of Radiology (ACR) Annual Meeting, Lung Cancer Screening: Implementations and Economic Considerations for a Screening Program

2015 Course co-director, American Roentgen Ray Society Lung Cancer Screening Symposium

2015 Invited speaker, American Roentgen Ray Society Lung Cancer Screening Symposium: Screening the Medicare Patient

### **Honors**

1986 Commendation for Distinguished Medical Service, South African Medical Corp

1997 Certificate of Merit, Scientific Exhibit - Thoracic FDG-PET: State of the Art, Radiological Society of North America

1999 Certificate of Merit, Scientific Exhibit - Solitary Pulmonary Nodule, American Roentgen Ray Society

1999 Cum Laude Certificate, Scientific Exhibit - Pulmonary Drug Toxicity: Radiologic-Pathologic Correlation, Radiological Society of North America

2001 Certificate of Merit, Scientific Exhibit - Radiation Injury of the Lung after 3-D Conformal Radiation Therapy, American Roentgen Ray Society

2001 Certificate of Merit, Scientific Exhibit - Radiation Injury of the Lung after 3-D Conformal Radiation Therapy, Radiological Society of North America

2001 Certificate of Merit, Scientific Exhibit - Vascular Lesions and Proliferations within the Thorax: A Radiologic-Pathologic Overview, American Roentgen Ray Society

2002 Certificate of Merit, Scientific Exhibit - Pleural Disease: Beyond Malignant Mesothelioma, American Roentgen Ray Society

2002 Certificate of Merit, Scientific Exhibit - The Retrotracheal Space: Normal Anatomy and Pathologic Appearances, American Roentgen Ray Society

Cum Laude Certificate, Scientific Exhibit - The Crazy-Paving Pattern on Thin-Section CT of the Lungs: A Radiologic-Pathologic Overview, Radiological Society of North America

2002 Cum Laude Certificate, Scientific Exhibit - The Retrotracheal Space: Normal Anatomy and Pathologic Appearances, European Congress of Radiology

2003 President's Award for Hypothesis-Driven Exhibit, Scientific Exhibit - The Crazy-Paving Pattern on Thin-Section CT of the Lungs: A Radiologic-Pathologic Overview, Society of Thoracic Radiology

2004 Certificate of Merit, Scientific Exhibit - Anatomy of the Pericardial Recesses on Multidetector CT: Implications for Oncologic Imaging, American Roentgen Ray Society

2004 Certificate of Merit, Scientific Exhibit - PET-CT in Patients with Non-Small Cell Lung Cancer: Normal Variants and Pitfalls, Radiological Society of North America

2009 Editor's Recognition Award, Journal of Thoracic Imaging

2010 Editor's Recognition Award, Journal of Thoracic Imaging

2011 Editor's Recognition Award, Journal of Thoracic Imaging

2012 Cum Laude Certificate, Scientific Exhibit - Multidetector CT Evaluation of Airway Stents: What the Radiologist Should Know, Society of Thoracic Radiology

2012 Cum Laude Certificate, Scientific Exhibit - Role of Multidetector CT in the Evaluation of Airway Stents, Radiological Society of North America

2012 Magna Cum Laude Certificate, Scientific Exhibit - Update in the Evaluation of

- the Solitary Pulmonary Nodule: Solid and Subsolid Lesions, Radiological Society of North America
- 2012 Certificate of Merit, Scientific Exhibit - Pitfalls in the Interpretation of PET/CT Findings in the Chest, 3rd World Congress of Thoracic Imaging
- 2013 Editor's Recognition Award, Journal of Thoracic Oncology
- 2014 Cum Laude Certificate, Scientific Exhibit - Pitfalls in the Interpretation of PET/CT Findings in the Chest, Society of Thoracic Radiology

**C. Peer-Reviewed Publications**(From 2011 of a total 134 peer-reviewed publications)

1. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG, M. D. Anderson Esophageal Cancer Group (Erasmus JJ), University of Rochester School of Medicine and Dentistry Foregut Group. Endoscopic esophageal tumor length; a prognostic factor for patients with esophageal cancer. *Cancer* 117(1):63-69, 1/2011. e-Pub 8/2010. PMID: 20803613.
2. National Lung Screening Trial Research Team (Erasmus JJ), Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The national lung screening trial: overview and study design. *Radiology* 258(1):243-253, 1/2011. e-Pub 11/2010. PMID: PMC3009383.
3. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discov* 1(1):44-53, 6/2011. e-Pub 6/2011. PMID: 22586319.
4. Marom EM, Milito MA, Moran CA, Liu P, Correa AM, Kim ES, Komaki R, Erasmus JJ, Hofstetter WL, Rice DC, Swisher SG. Computed tomography findings predicting invasiveness of thymoma. *J ThoracOncol* 6(7):1274-1281, 7/2011. PMID: 21623235.
5. Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, Giroux DJ, Hasegawa S, Kernstine KH, Waller D, Rami-Porta R, International Association for the Study of Lung Cancer International Staging Committee (Erasmus JJ) and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. *J ThoracOncol* 6(8):1304-12, 8/2011. PMID: 21847060.
6. National Lung Screening Trial Research Team (Erasmus JJ), Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 4(365(5)):395-409, 8/2011. e-Pub 6/2011. PMID: 21714641.
7. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. *Oncology* 82(2):108-113. e-Pub 2/2012. PMID: 22328056.
8. Amini A, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox J, Dong L, Welsh J. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. *Int J RadiatOncolBiolPhys* 82(3):e391-8, 3/2012. PMID: PMC3786565.
9. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I

clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. *PLoS One* 7(4):e34833, e-Pub 4/2012. PMID: PMC3338819. PMID: 22558101.

10. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. *J Thorac Oncol* 7(5):825-32, 5/2012. e-Pub 4/2012. PMID: PMC3465940.

11. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. *Ann Oncol* 23(10):2638-42, 10/2012. e-Pub 7/2012. PMID: PMC3457750.

12. Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. *Am J Clin Oncol*. e-Pub 10/2012. PMID: 23111360.

13. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. *Ann Thorac Surg* 94(4):1126-32; discussion 1132-3, 10/2012. e-Pub 8/2012. PMID: 22921233.

14. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. *Radiat Oncol* 7(1):144, 2012. e-Pub 8/2012. PMID: PMC3444399.

15. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. *Oncology* 83(5):300-304, 2012. e-Pub 9/2012. PMID: PMC3832345.

16. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. *J Thorac Oncol* 8(2):222-8, 2/2013. e-Pub 1/2013. PMID: PMC3549050.

17. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. *J Thorac Oncol* 8(4):436-42, 4/2013. e-Pub 2/2013. PMID: PMC3879952.

18. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J, National Lung Screening Trial Research Team (Erasmus JJ). Results of the two incidence screenings in the National Lung Screening Trial. *N Engl J Med* 369(10):920-31, 9/2013. PMID: 24004119.

19. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, University of Texas MD Anderson Esophageal Cancer Group. The influence of histopathologic tumor viability on long-term

survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. *Ann Surg* 258(3):500-7, 9/2013. PMID: 24022442.

20. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac (18)F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. *RadiotherOncol* 109(1):82-8, 10/2013. e-Pub 9/2013. PMID: 24016676.

21. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. *Ann Oncol* 24(11):2854-9, 11/2013. e-Pub 8/2013. PMID: 23994746.

22. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial. *Clin Cancer Res* 19(24):6967-75, 12/2013. e-Pub 10/2013. PMID: PMC3905243.

23. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K, Staging and Prognostic Factors Committee, Members of the Advisory Boards (Erasmus JJ), Participating Institutions of the Thymic Domain. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. *J ThoracOncol* 8(12):1467-73, 12/2013. PMID: 24389429.

24. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role? *J ThoracOncol* 9(8):1202-1206, 8/2014. PMID: 25157774.

25. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. *Oncologist* 19(10):1040-1, 10/2014. e-Pub 8/2014. PMID: PMC4201000.

26. Bhora FY, Chen DJ, Detterbeck FC, Asamura H, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P. Staging and Prognostic Factors Committee; Advisory Boards (Erasmus JJ). The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. *J ThoracOncol* 9(9 Suppl 2):S88-96, 2014. PMID: 25396317

27. Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom EM, Nicholson AG, Ruffini E; The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. Staging and Prognostic Factors Committee; Members of the Advisory Boards (Erasmus JJ); Participating Institutions of the Thymic Domain. *J ThoracOncol* 9(9 Suppl 2):S81-7, 2014. PMID: 25396316.

28. Nicholson AG, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom EM, Okumura M, Ruffini E, Van Schil P. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. Staging and

Prognostic Factors Committee; Members of the Advisory Boards (Erasmus JJ); Participating Institutions of the Thymic Domain. *J Thorac Oncol* 9(9 Suppl 2):S73-80, 2014. PMID: 25396315.

29. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards (Erasmus JJ); Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. *J Thorac Oncol* 9(9 Suppl 2):S65-72, 2014. PMID: 25396314.

30. Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. *Radiographics* 34(6):1707-21, 10/2014. PMID: 25310425.

31. Truong MT, Ko JP, Rossi SE, Rossi I, Viswanathan C, Bruzzi JF, Marom EM, Erasmus JJ. Update in the evaluation of the solitary pulmonary nodule. *Radiographics* 34(6):1658-79, 10/2014. PMID: 25310422.

32. Godoy MC, Saldana DA, Rao PP, Vlahos I, Naidich DP, Benveniste MF, Erasmus JJ, Marom EM, Ost D. Multidetector CT Evaluation of Airway Stents: What the Radiologist Should Know. *Radiographics* 34(7):1793-806, 11/2014. PMID: 25384279.

33. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members (Erasmus JJ) and Participating Institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. *J Thorac Oncol* 9(11):1618-24, 2014. PMID: 25436796.

34. Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG. Limitations of 18F-2-Deoxy-d-Glucose Positron Emission Tomography in N1 Detection in Patients With Pathologic Stage II-N1 and Implications for Management. *Ann Thorac Surg* 99(2):414-20, 2/2015. e-Pub 12/2014. PMID: 25497068.

35. Recondo G, Busaidy N, Erasmus J, Williams MD, Johnson FM. Spindle Epithelial Tumor with Thymus-like Differentiation (SETTLE): A Case Report and Comprehensive Review of the Literature and Treatment Options. *Head Neck* 37(5):746-54, 5/2015. e-Pub 5/2014. PMID: 24677409.

36. Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ, Buchholz TA, Giordano SH, Smith BD. Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival. *Radiother Oncol* 115(2):257-63, 5/2015. e-Pub 5/2015. PMID: 26013292.

#### **D. Invited Publications**(From 2011 of a total 37 invited publications)

1. Truong MT, Viswanathan C, Erasmus JJ. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. *J Thorac Imaging* 26(2):132-46, 5/2011. PMID: 21508735.

2. Welsh J, Amini A, Likhacheva A, Erasmus JJ, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. *Curr Oncol Rep* 13(3):157-67, 6/2011. PMID: 21365188.

3. Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. *Semin Nucl Med* 42(4):255-60, 7/2012. PMID: 22681674.

4. Godoy MC, Bruzzi JF, Viswanathan C, Truong MT, Guimarães MD, Hofstetter WL, Erasmus JJ, Marom EM. Multimodality imaging evaluation of esophageal cancer: staging, therapy assessment and complications. *Abdom Imaging* 38(5):974-93, 10/2013. e-Pub 5/2013. PMID: 23677485.

5. Erasmus JJ, Mawlawi O, Howard B, Patz EF. PET-CT: current applications and new developments in the thorax. *SeminRespirCrit Care Med* 35(1):145-56, 2/2014. e-Pub 1/2014. PMID: 24481767.
6. Huynh TT, Broadbent KC, Jacob AD, James S, Erasmus JJ. Screening for carotid artery stenosis. *SeminRoentgenol* 50(2):127-38, 4/2015. e-Pub 10/2014. PMID: 25770343.
7. Carter BW, Erasmus JJ. Acute Thoracic Findings in Oncologic Patients. *J Thorac Imaging*. e-Pub 3/2015. PMID: 25803363.
8. de Groot PM, Carter BW, Betancourt Cuellar SL, Erasmus JJ. Staging of Lung Cancer. *Clin Chest Med* 36(2):179-196, 6/2015. e-Pub 4/2015. PMID: 26024599.
9. Betancourt-Cuellar SL, Carter BW, Palacio D, Erasmus JJ. Pitfalls and limitations in non-small cell lung cancer staging. *SeminRoentgenol* 50(3):175-82, 7/2015. e-Pub 2/2015. PMID: 26002237.

**D. Chapters**(From 2011 of a total 38 chapters)

1. Vilar J, Erasmus JJ. Current concepts in diagnosis and staging of lung cancer. In: *Diseases of the Heart, Chest and Breast: Diagnostic Imaging and Interventional Techniques*. Ed(s) Hodler J, Schulthess GK, Zollikofer CL. Springer-Verlag, Inc.: Milan, Italy, 3-12, 2011.
2. Patz EF, Erasmus JJ. Management of malignant and parapneumonic pleural effusions and lung abscess with percutaneous drainage. In: *Handbook of Interventional Radiologic Procedures*. Ed(s) Kandarpa and Oruni. Lippincott Williams and Wilkins, 486-494, 2011.
3. Erasmus JJ. Staging, restaging and response evaluation of non-small cell lung cancer. In: *Diseases of the Heart, Chest and Breast: Diagnostic Imaging and Interventional Techniques*. Ed(s) Hodler J, Schulthess GK, Zollikofer, CL. Springer-Verlag. Inc.: Milan, Italy, 203-210, 2011.
4. Erasmus JJ, Stewart DJ, Komaki R, Swisher SG. Lung cancer. In: *Oncologic Imaging: A Multidisciplinary Approach*. Ed(s) Paul Silverman. Elsevier, Inc.: Philadelphia, PA, 35-61, 2012.
5. Benveniste MF, Herzog CE, Zage PE, Erasmus JJ. Primary mediastinal neoplasms. In: *Oncologic Imaging: A Multidisciplinary Approach*. Ed(s) Silverman PM. Elsevier, Inc.: Philadelphia, PA, 63-78, 2012.
6. Erasmus JJ, Kong F, Macapinlac HA. PET Imaging of Lung Cancer. In: *Thoracic Oncology: The IASLC Multidisciplinary Approach*. Ed(s) Pass HI, Scagliotti GV, Ball D. IASLC Press: Aurora, Colorado, 315-331, 2014.
7. Erasmus JJ, Marom EM, Huynh TT, and Patz EF. Radiological Imaging of Thoracic Abnormalities. In: *Surgery of the Chest, 9th*. Ed(s) Sabiston, Spencer. Elsevier, Inc.: Philadelphia, PA, 2014.
8. Christensen JD, Erasmus JJ, Patz EF. Catheter Drainage of Intrathoracic Collections. In: *Handbook of Interventional Radiologic Procedures*. Ed(s) K Kandarpa, L Machan, J Durham, 2015.
9. Betancourt Cuellar SL, Marom EM, Erasmus JJ. Imaging Lung Cancer. In: *Lung Cancer*. Ed(s) JA Roth, WK Hong, R Komaki. John Wiley & Sons, Inc., 2015.
10. Vilar J, Erasmus JJ. Update in the Diagnosis and Staging of Lung Cancer and staging of lung cancer. In: *Diseases of the Heart, Chest and Breast: Diagnostic Imaging and Interventional Techniques*. Ed(s) Hodler J, Schulthess GK, Zollikofer CL. Springer-Verlag, Inc.: Milan, Italy, 3-16, 2015.
11. Berkowitz Y, Erasmus JJ. Limitations of Noninvasive Staging in Lung Cancer. In: *Diagnosis and Staging of Lung Cancer: A Minimally Invasive Approach*. Ed(s) Bhutani M. Swisher S, Erasmus J, and Zwischenberger J. People's Medical Publishing House-USA: Shelton, CT, 2015.

**E. Abstracts**



1. Amini A, Welsh JW, Yang J, McBurney ML, Williamson RT, Karhade M, Allen PK, Erasmus JJ, Dong L, Liao Z. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. 53rd Annual American Society of Clinical Oncology Meeting, 2011.
2. Xiang Z, Wen H, Erasmus JJ, O'Reilly M, Komaki R, Cox JD, Chang JY. FDG uptake predicts recurrence and survival in patients with unresectable stage III non-small cell lung cancer treated with 74 Gy (RBE) Proton Therapy and Chemotherapy. 53rd Annual American Society of Clinical Oncology Meeting, 2011.
3. Marom EM, Moran CA, Liu P, Correa AM, Kim ES, Komaki R, Erasmus JJ, Hofstetter WL, Rice DC, Swisher SG. CT findings predicting invasiveness of thymoma. 40th Congress of the International Society of Oncology and Biomarkers, 10/2012.
4. Marks JL, Hofstetter W, Correa A, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus JJ, Chang J, Maru D, Lee JH, Lee, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Society of Thoracic Surgery 48th Annual Meeting, 2012.
5. Sepesi B, Correa AM, Pataer A, Kalhor N, Bekele BN, Erasmus JJ, Hofstetter WL, Kim E, Komaki R, Mehran R, Moran CA, Papadimitrakopoulou V, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, William W, Wistuba I, Swisher SG. The impact of histopathologic response on pathologic TNM lung cancer staging system (AJCC Seventh) following neoadjuvant chemotherapy. Society of Thoracic Surgeons 49th Annual Meeting, 1/2013.
6. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebuena N, Banchs J, Komaki R, Welsh JW. Cardiac isodose distributions and increases in focal 18F-Fluorodeoxyglucose Uptake on positron emission tomography after thoracic stereotactic ablative radiotherapy. American Society of Radiation Oncology 55th Annual Meeting, 9/2013.
7. Francis AM, Correa AM, Betancourt-Cuellar SL, Kim JY, Sepesi B, Ajani JA, Komaki R, Erasmus JJ, Maru D, Munden RF, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Hofstetter WL, Swisher SG. Esophageal tumor thickness on computed tomography as a predictor of residual tumor in esophageal adenocarcinoma following preoperative chemoradiation. 9th Annual Academic Surgical Congress, 2/2014.
8. Betancourt Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Swisher SG, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal cancer: does FDG-PET/CT have a role. 114th Annual Meeting of the American Roentgen Ray Society, 5/2014.
9. Sorensen J, Erasmus JJ, Shroff G, Rao A, Stingo F, Court L, Gold KA, Lee J, Heymach JV, Swisher S, Godoy MC. Combining CT texture analysis with semantic imaging descriptions for the radiogenomic detection of EGFR and KRAS mutations in NSCLC, 16th World Conference on Lung Cancer (WCLC 2015), Denver, CO, 9/2015

## **F.Research Support**

### **Funded**

Collaborator, A phase I study of a continuous infusion of TNP-470 alone or with a combination of paclitaxel and carboplatin in adult patients with solid tumors, ID99-267, PI - R. Herbst, 1999-present, \$450,000, TAP Holdings, Inc.

Collaborator, A randomized, double-blind, phase III comparative trial of 2 doses of ZD1839 (IRESSA) in combination with paclitaxel and carboplatin versus placebo in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced (stage III or IV) non-small cell lung cancer, DM0-129, PI - R. Herbst, 2000-present, \$450,000, Zeneca Pharmaceuticals, Inc.

Collaborator, Phase I trial of Gleevec (imatinibmesylate), cisplatin and irontecan for patients with small-cell lung cancer, ID01-576, PI - S. Silberman, 2002-2005, Novartis Pharmaceuticals

Collaborator, A Phase II, open-label, multicenter study to evaluate the effect of tumor-based HER2 activation on the efficacy of RHUMAB 2C4 (PERTUZUMAB) in subjects with advanced (stage IIIB or IV) non-small cell lung cancer, ID03-0247, PI - R. S. Herbst, 2003-present, Genetech, Inc., and Hoffman La Roche

Collaborator, Accurate quantification of small lung nodules based on PET/CT images, RCR03-0503, PI - O. Mawlawi, 2003-present, \$24,000

Collaborator, Phase I study of intravenous DOTAP: Cholesterol-FUS1 liposome complex in patients with advanced non-small cell lung cancer previously treated with chemotherapy, ID00-123, PI - D. J. Stewart, 2003-present, MDACC

Collaborator, A multicenter phase II trial of neo-adjuvant pemetrexed (Alimta) plus cisplatin followed by surgery and radiation for pleural mesothelioma, 2004-0365, PI - K. M. Pisters, 2004, Eli Lilly

Collaborator, Pilot study measuring the feasibility of image guidance with PET/CT and motion control using feedback-guided breath-hold technique for esophagus intensity-modulated radiation therapy, 2003-0950, PI - Z. Liao, 2005, Radiological Society of North America

Collaborator, A phase II study of sorafenib in chemorefractory patients with advanced non-small cell lung cancer, 2005-0827, PI - G. R. Blumenschein, Jr., 2006, Bayer, Department of Defense

Collaborator, A phase III trial of oral suberoylanilidehydroxamic acid in patients with advanced Malignant pleural mesothelioma previously treated with systemic chemotherapy, 2005-0420, PI - G. R., Blumenschein, Jr., 2006, Merck Sharp and Dohme

Collaborator, A comparative study of gross tumor volume definition with or without PET fusion for patients with non-small cell lung carcinoma, RTOG0515, PI - M. K. Bucci, 2007, RTOG Yamaha

Collaborator, A double-blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3+AS15 antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive non small cell lung cancer, 2007-0865, PI - D. Rice, 2007, GlaxoSmithKline

Collaborator, A pilot study of radiofrequency ablation in high-risk patients with stage IA non-small cell lung cancer, ACOSGZ4033, PI - K. Ahrar, 2007, American College of Surgeons

Co-Chair, Phase I/II Clinical Trial combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer, 2011-0432, PI - C. Lu, 2011-present, Convergen Life Sciences

Collaborator, A phase III, open-label, randomised, multi-center, international study of MEDI4736, given as monotherapy or in combination with tremilumumab, determined by PD-L1 expression, versus standard of care in patients with locally advanced or metastatic non-small cell lung cancer (stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements (ARCTIC), 2014-0983, PI - Ferrarotto R, 2014-present, Astra Zeneca

Collaborator, A phase III, randomised, D+-ouble-blind, placebo-controlled, multi-centre, international study of MEDI4736 as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (Stage III) who have not progressed following definitive, platinum-based concurrent chemoradiation therapy (PACIFIC), 2014-1025, 2014-present, Astra Zeneca

Collaborator, Tumor mutation status will predict metabolic response to metformin in NSCLC, 1R21CA182964-01A1, PI - Skinner, 2014-present, \$457,000 (\$207,000/year), NIH/NCI

### **Unfunded**

Collaborator, Helical CT screening for lung cancer in patients previously treated for laryngeal cancer, ID01-307, PI - Munden R, 2001

Collaborator, A randomized, double-blind, multicenter, phase II study to assess the safety, tolerability, and efficacy of ZD6474 in combination with docetaxel (TAXOTERE) in subjects with locally advanced or metastatic non-small cell lung cancer, ID02-294, PI - R. S. Herbst, 2002-present

Collaborator, Continuing access to the tyrosine kinase inhibitor or VEGFR-2, AG013736 (A406) for patients previously receiving AG013736 in clinical trials, ID02-660, PI - R. S. Herbst, 2003-present

Collaborator, Comparison of CT and MRI in the preoperative Localization of abnormal parathyroid glands in patients with hyperparathyroidism, 2004-0378, PI - M. Truong, 2004

Collaborator, Minimally invasive esophagectomy, ECOG E2202, 2005-present

Collaborator, A phase I/II study of TARCEVA (erlotinib) in combination with chemoradiation in patients with stage IIIA/B non-small cell lung cancer (NSCLC), 2005-1023, PI - R. R. Komaki, 2006-present

Collaborator, Phase I trial using serial 4-D CT/PET in early assessment of tumor response for cancer of the esophagus treated with concurrent intensity modulated radiotherapy (IMRT) and chemotherapy, 2006-0058, PI - Z. Liao, 2006-present

Collaborator, Phase I/II clinical trial using respiratory-motion-controlled (RMC) image guided (IG) proton irradiation and concurrent chemotherapy for inoperable or unresectable esophageal cancer, 2006-0345, PI - Z. Liao, 2006-present

Collaborator, Clinical utility of integrated PET-CT imaging in therapeutic response assessment in patients receiving neoadjuvant therapy for esophageal carcinoma, RCR06-0663, PI - G. Gladish, 2006

Collaborator, Diagnosis of richter's transformation of CLL by PET-CT imaging, RCR06-0101, PI - J. Bruzzi, 2006

Collaborator, Short-term restaging of patients with non-small-cell lung cancer, RCR05-0962, PI - J. Bruzzi, 2006

Collaborator, Phase IB open-label, multicenter study to investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess the efficacy and safety of oral LBH589 in patients with advanced or metastatic non-small cell lung cancer or malignant pleural mesothelioma, 2007-0644, PI - V. Papadimitrakopoulou, 2007-present

Collaborator, Prospective comparison of endobronchial ultrasound needle biopsy versus mediastinoscopy for staging of mediastinal nodes in patients with clinical stage IIIA non-small cell lung cancer, 2007-0353, PI - D. Rice, 2007

Collaborator, A biomarker-integrated study in chemorefractory patients with advanced non-small cell lung cancer, 2005-0823, PI - K. Edward, 2008-present

Co-Principal Investigator, A phase I dose-escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including Phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer (CAUY922A2101), 2007-0927, PI - V. Papadimitrakopoulou, 2008-present

Collaborator, A phase II study of erlotinib (Tarceva) in combination with bexarotene (Targretin) in chemorefractory patients with advanced non-small cell lung cancer, 2005-0826, PI - K. Edward, 2008-present

Collaborator, A phase II study of sorafenib (BAY 43-9006) in chemorefractory patients with advanced non-small cell lung cancer, 2005-0827, PI - G. Blumenschein, 2008-present

Collaborator, A phase II, open label study of erlotinib (Tarceva) in previously treated subjects with advanced non-small cell lung cancer, 2005-0824, PI - K. Edward, 2008-present

Collaborator, A phase II, open label study of ZD6474 in previously treated subjects with advanced non-small cell lung cancer, 2005-0825, PI - A. S. Tsao, 2008-present

Study Chairman, Long-term follow-up of small (<4-mm) nodules detected by CT in oncology patients: A retrospective review, DR08-0031, 2008-present

Co-Principal Investigator, Positron emission tomography pre- and post-treatment assessment for locally advanced nonsmall cell lung carcinoma, RTOG-0235, PI - R. R. Komaki, 2008-present

Collaborator, Phase I-II study of dasatinib and erlotinib in non-small cell lung cancer, 2008-0353, PI - F. M. Johnson, 2008

Collaborator, A multi-center study of biomarker modulation by inhibition of EGFR and/or Src family kinases using erlotinib and dasatinib in head and neck and lung cancers, 2009-0411, PI - F. M. Johnson, 2009

Collaborator, A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus, ACOSOGZ4051, PI - W. L. Hofstetter, 2009

Collaborator, BATTLE - 2 Program: A biomarker-integrated study in previously treated patients with advanced non-small cell lung cancer, 2009 - 0360, PI - V. Papadimitrakopoulou, 2009

Collaborator, BATTLE-FL: A biomarker-integrated study in patients with advanced non-small cell lung cancer treated in the front-line (FL) setting, 2010-0097, PI - E. Kim, 2010

Collaborator, Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus, 2010-0743, PI - V. Papadimitrakopoulou, 2010

Co-Principal Investigator, Gene therapy combined with erlotinib for stage 4 lung cancer patients, DOTAP:TUSC2/FUS1, PI - Roth JA, 2011

Study Chairman, Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening, 2013-0609, 2013-present

Collaborator, Clinical staging of malignant pleural mesothelioma (MPM) by volumetric computed tomography imaging, PA13-0470, 2013-present

Collaborator, Phase I study of induction cisplatin, docetaxel and nintedanib for stage IB-III A non-small cell lung cancers amenable for surgical resection, 2013-0844, 2013-present

Collaborator, The International Association for the Study of Lung Cancer (IASLC) Volumetric CT Ancillary Feasibility Study to the Prospective Malignant Pleural Mesothelioma Staging Project, PA13-0470, 2013-present

Collaborator, A Phase I Dose Escalation Study of OMP-52M51 in Subjects with Solid Tumors, 52M51-002, 2014-present

Collaborator, A Phase I/II, Open Label, Safety, PK and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR NSCLC, 2012-0009, 2014-present

Collaborator, Dual-Energy Computed Tomography (DECT) Evaluation For Prediction Of Response To Neoadjuvant Therapy In Non-Small Cell Lung Cancer (NSCLC), 2014-1070, 2014-present

Collaborator, Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy, 2014-0589, 2014-present

Collaborator, Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacytidine in Advanced Non-Small Cell Lung Cancer, 2012-0134, 2014-present

Collaborator, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC, NRG-LU001, PI - TheodorosTsakiridis, 2014-present

Collaborator, A Phase 1 Study of MEDI6383 (an OX40 Agonist) in Adult Subjects with Select Advanced Solid Tumors, 2015-0055, 2015-present